We demonstrate that CTAB measures aspects of the tumor microenvironment not assessed by traditional biomarkers of immunotherapy response, namely Programmed Death-Ligand 1 (PD-L1) expression and tumor mutational burden (TMB). The gene discussed is CD274; the disease is neoplasm.